BofA Securities Downgrades Rhythm Pharmaceuticals (RYTM) to Neutral
- Wall Street ends down as data spooks investors awaiting Fed report
- Roblox (RBLX) Lower as DAUs Fall Sequentially
- DraftKings (DKNG) Plunges as Hindenburg's Report Indicates Betting Company's Links to Black Market Operations
- Oracle (ORCL) Tops Q4 EPS by 23c
- U.S. retail sales take step back as spending pivots to services, trend remains strong
Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
BofA Securities downgraded Rhythm Pharmaceuticals (NASDAQ: RYTM) from Buy to Neutral with a price target of $33.00.
Shares of Rhythm Pharmaceuticals closed at $29.27 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: Piper Sandler Downgrades Principal Financial Group (PFG) to Neutral, Outperformance Unlikely to Continue
- Raymond James Downgrades Nutrien (NTR) to Outperform
- Scotiabank Downgrades Grupo Aeroportuario del Centro (OMAB:MM) (OMAB) to Sector Underperform
Create E-mail Alert Related CategoriesDowngrades
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!